Eli Lilly and Company Stock Performance
Eli Lilly and Company shares traded at $1,179.27, reflecting a daily decline of approximately 1.66% per SID market data. Over the trailing one-month period, LLY posted a modest gain of 4.04%, while the three-month return registered a slight decline of 1.6%. On a one-year basis, the stock has appreciated 9.14%, underperforming broader market indices during the same timeframe. Technically, LLY trades marginally above its 50-day moving average of $1,173.48 and well above its 200-day moving average of $1,070.17, according to SID market data. The 14-day relative strength index stands at 54.7, indicating neutral momentum with no immediate overbought or oversold conditions. The stock's beta of 0.369 reflects significantly lower volatility relative to the broader market. Average daily trading volume is approximately 3.8 million shares, supporting adequate liquidity for the company's $906.5 billion market capitalization.
Eli Lilly and Company Valuation Analysis
Eli Lilly currently trades at a price-to-earnings ratio of 49.16, a substantial premium to the broader Healthcare sector average, per SID market data. The PEG ratio stands at 1.47, suggesting the valuation remains elevated even when adjusting for anticipated earnings growth, though it falls below the commonly cited threshold of 2.0 that indicates significant overvaluation relative to growth. The price-to-book ratio of 38.04 reflects the market's substantial premium for Eli Lilly's intangible assets, including its GLP-1 receptor agonist franchise and robust pipeline, according to SEC filings. The company offers a dividend yield of approximately 0.59%, positioning it as a modest income generator relative to healthcare peers. With a market capitalization of $906.5 billion, Eli Lilly remains one of the most highly valued pharmaceutical companies globally. These valuation multiples indicate the market is pricing in significant future revenue and earnings expansion from its key therapeutic platforms.
Smart Money Activity for LLY
Eli Lilly's composite smart money score stands at 44 out of 100, generating a neutral signal per SID market data. The institutional component scores a perfect 25 out of 25, indicating extremely strong interest from large asset managers and funds as reflected in 13F institutional filings. In contrast, the insider trading component scores 7.2 out of 25, with SEC Form 4 filings showing 16 insider transactions over the past 90 days, comprising 9 purchases and 7 sales. This relatively balanced buy-to-sell ratio suggests insiders are not signaling a strong directional conviction. The dark pool activity score of 9.1 out of 25 indicates moderate levels of off-exchange institutional trading. Congressional trading activity scores just 3.2 out of 25, reflecting minimal disclosed positions by members of Congress. The divergence between the maximum institutional score and the below-average insider and dark pool scores creates the overall neutral composite reading, suggesting that while large institutional holders maintain strong positions, other smart money indicators do not confirm a clear directional bias.
Eli Lilly and Company Earnings Outlook
Eli Lilly has delivered consecutive earnings beats in its two most recently reported quarters, according to company earnings reports. In the quarter reported on August 5, 2026, actual earnings per share came in at $8.38 versus a consensus estimate of $6.01, representing a positive surprise of $2.37 or approximately 39.4%. The quarter reported on April 30, 2026 similarly exceeded expectations, with actual EPS of $8.55 compared to estimates of $6.85, a $1.70 positive surprise. Looking ahead, analyst estimates project EPS of $8.84 for the quarter expected on August 6, 2026, and $9.28 for the quarter anticipated on October 29, 2026, per analyst estimates. The sequential increase in forward estimates reflects expectations for continued revenue acceleration. The magnitude of recent earnings surprises, averaging over $2.00 per share across the last two quarters, underscores the degree to which Eli Lilly's operational performance has outpaced Wall Street projections.
Wall Street Analyst Ratings for LLY
Wall Street consensus on Eli Lilly remains uniformly bullish, with all five most recent analyst actions reaffirming positive ratings, per Wall Street analyst reports. On October 8, 2026, Cantor Fitzgerald maintained its Overweight rating, followed by Morgan Stanley reiterating Overweight on October 7. JP Morgan maintained its Overweight stance on September 28, while TD Cowen reiterated a Buy rating on September 22 and Guggenheim maintained its Buy on September 18, according to SID consensus data. Notably, none of the recent actions involved upgrades or downgrades, indicating sustained conviction rather than shifting sentiment. The consistency across major bulge-bracket and boutique firms reflects broad institutional agreement on Eli Lilly's growth trajectory. All five analysts represent prominent research franchises spanning different coverage styles, from large-cap generalists to specialized healthcare analysts. The absence of any Hold or Sell ratings among recent coverage actions positions LLY with a unanimous positive consensus across this sample of analyst activity.
